Dana E. Rathkopf, MD
Chair, Research Council; Associate Vice Chair, Faculty Development, Department of Medicine
Prostate Cancer; Other Genitourinary Cancers; Clinical Trials
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Rathkopf accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Tulane School of Medicine
Internal Medicine - New York University Hospital
Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center; Medicine - Weill Cornell Medical College
I am a board-certified medical oncologist who works as part of a multidisciplinary team to treat people with prostate cancer and other genitourinary cancers. My primary focus is on the medical treatment of men with advanced or high-risk prostate cancer. I have been doing this work for more than a decade.
I also develop and design clinical trials testing new treatments for my patients. These involve agents that are targeted to androgen receptor (AR) signaling and other molecular pathways that allow the disease to grow and spread. The outlook for men with advanced prostate cancer, also known as castration-resistant prostate cancer (CRPC), has changed dramatically over the past five years thanks to advances in systemic therapies. Drug development has shifted from standard chemotherapy to targeted approaches based on a fundamental understanding of the makeup of the disease biology. One impressive example of the success of this approach was the discovery that androgen receptor overexpression is associated with resistance to conventional anti-androgens. Accompanying this discovery has been the development of AR targeted therapies that block the growth of castration-resistant prostate cancer, such as the AR antagonist enzalutamide (Xtandi®) and the androgen synthesis inhibitor abiraterone acetate (Zytiga®).
I have had a leadership role in clinical trials using these next-generation AR targeted therapies for patients with advanced prostate cancer who have not yet received chemotherapy. The survival benefits shown in these trials changed the standard of care for patients. I am now focused on improving outcomes for patients in need by using new AR-directed therapies and combinations of targeted agents.
On a national level, I am the site principal investigator at MSK for the Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. I also serve as co-chair of the American Society of Clinical Oncology Genitourinary Guidelines Advisory Group.
Although I do a lot of work on clinical trials in an effort to bring new and more-effective treatment options into clinical practice, my first priority is always my patients. Many of them ask me why I became interested in a disease that affects only men. In addition to my interest in the unique biology of the prostate cancer disease pathway, and the opportunity to work with extraordinary mentors and colleagues, I am also a daughter, wife, and mother of three sons. The choice to pursue a career in prostate cancer was an easy one for me.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2019-2020)
- Excellence in Internal Medicine, American College of Physicians
- ASCO/AACR (American Association for Cancer Research) Workshop: Methods in Clinical Cancer Research, ASCO Merit Award
- Prostate Cancer Foundation Young Investigator Award
- Clinical Trials Investigated by Dr. Rathkopf
- A Phase I Study of CC-94676 in Men with Metastatic Castration-Resistant Prostate Cancer
- A Phase I Study of PT-112 Immunotherapy in Men with Metastatic Castration-Resistant Prostate Cancer
- A Phase II Study of Abiraterone Acetate, Atezolizumab Immunotherapy, Leuprolide, and Radiation Therapy in Men with Newly Diagnosed Metastatic Prostate Cancer
- A Phase III Study of Abiraterone Acetate and Prednisone with and without Niraparib to Treat Metastatic Prostate Cancer with Certain Genetic Changes
- Clinical Trials Co-Investigated by Dr. Rathkopf
- A Phase III Study of Hormonal Therapy with Apalutamide or a Placebo in Men with High-Risk Localized or Locally Advanced Prostate Cancer Before Prostate Removal Surgery
- Two Studies for Patients with Unfavorable Intermediate-Risk Prostate Cancer Assessing Less Intense Treatment for Those With a Low Gene Risk Score and a More Intense Treatment for Those with a Higher Gene Risk Score
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study
Visit PubMed for a full listing of Dr. Rathkopf’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dana E. Rathkopf discloses the following relationships and financial interests:
Janssen Research & Development, LLC
Provision of Services (uncompensated)
Provision of Services (uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.